EMVision Medical Devices Ltd (ASX:EMV) is focused on the development and commercialisation of innovative neurodiagnostic technology. The Company’s first commercial product is a portable, cost effective, non-ionising and non-invasive bedside brain scanner device known as the emu™. EMVision’s second commercial product is an ultra-light weight pre-hospital device (First Responder). EMVision’s first indication is in stroke care, with a planned second indication in traumatic brain injury assessment.

EMVision was founded in 2017 following a decade of research out of the University of Queensland. EMVision has a significant IP portfolio and has invested over $50m in the development of its novel technology, including $20m of grant funding and a $15m strategic investment from Keysight Technologies (KEYS.NYSE).

Watch: Portable brain scanner to reduce diagnosis and treatment time

KEY PEOPLE

  • Scott Kirkland - CEO and Managing Director

    Scott is the co-founder of EMVision Medical Devices Ltd (ASX:EMV). Scott has held several senior sales positions, including Head of Client Sales at Quantcast, a US-based technology company, prior to establishing EMVision as a leader in innovative neurodiagnostic technology. Scott is a member of the Australian Institute of Company Directors.

    read more

  • Prof Stuart Crozier – Chief Scientific Officer

    Co-inventor of EMVision’s underlying technology, Professor Stuart Crozier is also the former Director of Biomedical Engineering at the University of Queensland. Professor Crozier’s advancements in MRI technology have been used in billions of scans around the world and are now central to 65% of all MRI machines manufactured since 1997.

    read more

  • Forough Khandan – Chief Technology Officer

    Prior to EMVision, Forough was Program Manager at Nanosonics (ASX:NAN), reporting directly to the CTO, where she led a large multi-disciplined team of engineers and scientists across the business. During her 9-year tenure at Nanosonics, Forough successfully planned and executed highly complex new technology and product development programs and was key in leading activities required to define, develop, and deliver Nanosonics’ new products including the second generation of trophon device from prototype to after-market release.

    read more

RELATED STOCKHEAD STORIES